Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis

被引：4
|
作者：
John, Nevin [1 ]
Carroll, Antonia [2 ]
Brownlee, Wallace J. [2 ,3 ]
Chataway, Jeremy [1 ,2 ]
机构：
[1] UCL, Inst Neurol, Neuroinflammat, London WC1N 3BG, England
[2] Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, London, England
[3] Queen Sq Multiple Sclerosis Ctr, Dept Neuroinflammat, London, England
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2019年 / 90卷 / 12期
关键词：
FINGOLIMOD;
D O I：
10.1136/jnnp-2019-320687
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1376 / +
页数：3
相关论文
共 50 条
  • [21] Natalizumab improves physical disability in patients with relapsing multiple sclerosis
    Giovannoni, G.
    Munschauer, F.
    O'Connor, P. W.
    Phillips, J. T.
    Polman, C. H.
    Pace, A.
    Kim, R.
    Panzara, M. A.
    JOURNAL OF NEUROLOGY, 2009, 256 : S124 - S124
  • [22] Natalizumab reduces visual loss in patients with relapsing multiple sclerosis
    Balcer, L. J.
    Galetta, S. L.
    Calabresi, P. A.
    Confavreux, C.
    Giovannoni, G.
    Havrdova, E.
    Hutchinson, M.
    Kappos, L.
    Lublin, F. D.
    Miller, D. H.
    O'Connor, P. W.
    Phillips, J. T.
    Polman, C. H.
    Radue, E.-W.
    Rudick, R. A.
    Stuart, W. H.
    Wajgt, A.
    Weinstock-Guttman, B.
    Wynn, D. R.
    Lynn, F.
    Panzara, M. A.
    NEUROLOGY, 2007, 68 (16) : 1299 - 1304
  • [23] Switching From Natalizumab To Immune Reconstitution Therapies In Patients With Multiple Sclerosis
    Matos, Sara
    Cunha, Carolina
    Bernardes, Catarina
    Cardoso, Joao
    Campelo, Isabel
    Feio, Jose
    Batista, Sonia
    Nunes, Carla
    Macario, Maria do Carmo
    Sousa, Livia Maria
    Correia, Ines
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 931 - 931
  • [24] Alemtuzumab: A Review of Its Use in Patients with Relapsing Multiple Sclerosis
    Karly P. Garnock-Jones
    Drugs, 2014, 74 : 489 - 504
  • [25] Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients
    Wang, Li
    Qi, Chun-Hui
    Zhong, Ren
    Yuan, Chao
    Zhong, Qiu-Yue
    MEDICINE, 2018, 97 (08)
  • [26] Alemtuzumab: A Review of Its Use in Patients with Relapsing Multiple Sclerosis
    Garnock-Jones, Karly P.
    DRUGS, 2014, 74 (04) : 489 - 504
  • [27] The sequential natalizumab - alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial - Part I: Rationale and objectives
    Hussain, Rehana Z.
    Sguigna, Peter, V
    Okai, Annette
    Wright, Crystal
    Madinawala, Mariam
    Bass, Ann D.
    Cutter, Gary R.
    Manouchehri, Navid
    Stuve, Olaf
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2022, 14
  • [28] High risk PML patients switching from natalizumab to alemtuzumab
    Bertolotto, Antonio
    Capobianco, Marco
    Lo Re, Marianna
    Malentacchi, Maria
    Sperli, Francesca
    Matta, Manuela
    Di Sapio, Alessia
    Malucchi, Simona
    NEUROLOGY, 2017, 88
  • [29] An update on the safety of natalizumab in patients with relapsing multiple sclerosis: Results from touch and TYGRIS
    Bozic, C.
    Belcher, G.
    Kooijmans, M.
    Kim, R.
    Lynn, F.
    Panzara, M. A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 320 - 320
  • [30] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
12345